Stem Cells Spin (WAR:SCS) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:SCS Stem Cells Spin SA WAR:SCS
26 GF Score
Price zł0.41
GF Value zł0.10
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Stem Cells Spin 5-Year Yield-on-Cost %?

Stem Cells Spin WAR:SCS +9.63% 26 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus rates WAR:SCS with a GF Score™ of 26/100 and a GF Value™ of zł0.10 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 153 Biotechnology companies, Stem Cells Spin ranks worse than 653594.12% on this metric.

Stem Cells Spin's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Stem Cells Spin's 5-Year Yield-on-Cost % or its related term are showing as below:



WAR:SCS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Stem Cells Spin  (WAR:SCS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Stem Cells Spin 5-Year Yield-on-Cost % Related Terms


WAR:SCS vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Stem Cells Spin's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stem Cells Spin 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's 5-Year Yield-on-Cost % falls into.


WAR:SCS
26GF Score
Stem Cells Spin SA WAR:SCS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stem Cells Spin 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Stem Cells Spin is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Stem Cells Spin (WAR:SCS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Stem Cells Spin and its competitors. According to the industry distribution chart, Stem Cells Spin ranks #999999 out of 153 companies in the Biotechnology industry.
Is Stem Cells Spin's 5-Year Yield-on-Cost % too high?
Stem Cells Spin's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Stem Cells Spin ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stem Cells Spin has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stem Cells Spin's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stem Cells Spin ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Stem Cells Spin in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.69, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Stem Cells Spin and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stem Cells Spin's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stem Cells Spin stock overvalued right now?
Based on GuruFocus' analysis, Stem Cells Spin (WAR:SCS) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.10, compared to a current price of zł0.41 — trading 310% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Stem Cells Spin's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Stem Cells Spin (WAR:SCS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stem Cells Spin (WAR:SCS) Overvalued in 2026?

Based on GuruFocus' analysis, Stem Cells Spin stock appears to be overvalued. The current stock price of zł0.41 is trading 310% above its estimated GF Value™ of zł0.10. GuruFocus considers Stem Cells Spin to be Significantly Overvalued.

Key valuation signals for WAR:SCS:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: zł0.10 vs. price of zł0.41 (310% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the WAR:SCS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Stem Cells Spin Business Description

Address Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141
Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing, and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1, and Velvetyna.
26GF Score

Get the complete analysis for WAR:SCS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.41
Price
zł0.10
GF Value